

Targeting Success in Oncology




Business Strategy

- Landscape evaluation of oncology indications to identify patient subsets expected to have remaining unmet needs in the near future
- Development of an economic impact model to support commercialization of a novel prognostic test for early-stage cancer management
- Competitive positioning strategy in rapidly evolving leukemia and lymphoma treatment landscapes
- Commercialization strategy from clinical trial design through partnership for novel chemotherapeutic for solid tumors
- Strategic plan for tumor ablation business unit of a large medical device company
- Commercialization strategy for a novel diagnostic to detect circulating tumor cells
- Indication prioritization for a portfolio of kinase inhibitors
- Creation of a business plan for an intra-operative cancer detection tool



Opportunity Assessment

- US, Europe and Asia market assessment for novel kinase inhibitors being developed for multiple solid tumor types
- Multi-country forecasts for a targeted therapy in Phase II development for AML and MDS
- Developed a bottoms-up monthly forecast for a novel cell-based tumor vaccine
- Opportunity evaluation for novel prognostic diagnostic guiding adjuvant therapy decision making
- Market forecast to support commercialization of a next-generation sequencing based cancer test
- Market opportunity of novel in vivo patient dose monitoring technology for therapeutic radiation oncology
- Market assessment for subcutaneous reformulations of currently marketed intravenous targeted therapies
- Opportunity assessment for biosuperior versions of leading oncology biologics



Clinical Trial Strategy

- Clinical trial design for companion diagnostic technology in solid tumors
- Assessment of clinical trial strategy and impact on positioning in hormone refractory prostate cancer
- Trial assessment for products targeting mTOR and IGF1R pathways
- Evaluation of clinical trial design options for pancreatic cancer
- Strategies to improve trial design, management, and outcomes in multiple myeloma
- Clinical trial strategy for novel diagnostic platform to diagnose early-stage cancer
- Clinical trial strategy for novel, non-EPO, mechanism for correction of chemotherapy-induced anemia



M&A/Partnerships

- In-depth analysis of immuno-oncology assets in development for hematological malignancies to identify potential partnerships
- Valuation and deal support for novel, blockbuster oncology therapeutic
- Developed deal terms for three potential partnerships for early-stage oncology diagnostic
- Due diligence of a novel breast biopsy technology
- Comprehensive oncology screen prioritizing acquisition and licensing targets to fill pipeline behind first launched product
- Evaluation of potential sales and marketing partner for a novel lymphoma therapy
- Acquisition diligence of an oncology supportive care product

Expertise in Specific Types of Cancer

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- B-Cell Lymphoma
- Basal Cell Carcinoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Cervical Cancer/HPV
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myelogenous Leukemia (CML)
- Colorectal Cancer
- Diffuse large B-cell Lymphoma (DLBCL or DLBL)
- Gastric Cancer
- Head and Neck Cancers
- Kaposi's Sarcoma
- Kidney/Renal Cancer
- Liver Cancer
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Melanoma
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Sarcoma
- Squamous Cell Carcinoma
- Testicular Cancer
- Thyroid Cancer
- Uterine Cancer